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Abstract
Introduction: Influenza accounts for 5 to 10% of community-acquired pneumonias and is a major cause of mortality. 
Sterile and bacterial lung injuries are associated with procoagulant and inflammatory derangements in the lungs. 
Activated protein C (APC) is an anticoagulant with anti-inflammatory properties that exert beneficial effects in models 
of lung injury. We determined the impact of lethal influenza A (H1N1) infection on systemic and pulmonary 
coagulation and inflammation, and the effect of recombinant mouse (rm-) APC hereon.
Methods: Male C57BL/6 mice were intranasally infected with a lethal dose of a mouse adapted influenza A (H1N1) 
strain. Treatment with rm-APC (125 μg intraperitoneally every eight hours for a maximum of three days) or vehicle was 
initiated 24 hours after infection. Mice were euthanized 48 or 96 hours after infection, or observed for up to nine days.
Results: Lethal H1N1 influenza resulted in systemic and pulmonary activation of coagulation, as reflected by elevated 
plasma and lung levels of thrombin-antithrombin complexes and fibrin degradation products. These procoagulant 
changes were accompanied by inhibition of the fibrinolytic response due to enhanced release of plasminogen 
activator inhibitor type-1. Rm-APC strongly inhibited coagulation activation in both plasma and lungs, and partially 
reversed the inhibition of fibrinolysis. Rm-APC temporarily reduced pulmonary viral loads, but did not impact on lung 
inflammation or survival.
Conclusions: Lethal influenza induces procoagulant and antifibrinolytic changes in the lung which can be partially 
prevented by rm-APC treatment.
Introduction
Influenza A infection is a major cause of morbidity and
mortality: Seasonal influenza A infection causes over
200,000 hospitalizations and approximately 41,000 deaths
in the United States annually, being the seventh leading
cause of mortality [1]. Besides its regular seasonal charac-
ter, influenza A, due to the introduction and adaptation
of novel hemagglutinin subtypes from other mammals or
birds resulting in antigenic shifts, has the potential to
cause pandemics, as the pandemics in 1918, 1957 and
1968 have shown [2]. Currently, a novel influenza A
(H1N1) strain from swine origin has evolved to a pan-
demic, now worldwide causing major concern for the
near future [3]. Although the greatest proportion of mor-
tality caused by influenza A infection is due to secondary
bacterial pneumonia and cardiovascular complications,
influenza itself is also an important cause of community-
acquired pneumonia (CAP), causing 5 to 10% of CAP-
cases [4-7]. As such, influenza is a major concern for pul-
monologists and intensive care physicians [8].
Severe infection and inflammation have been closely
linked to activation of coagulation and downregulation of
anticoagulant mechanisms and fibrinolysis [9]. In bacte-
rial pneumonia, pulmonary activation of coagulation as
well as downregulation of the anticoagulant protein C
(PC) pathway and fibrinolysis have been demonstrated
[10-12]. Beside anticoagulant properties, activated (A)PC
has been shown to have profibrinolytic, anti-inflamma-
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tory, anti-apoptotic and other cytoprotective properties
[13]. Downregulation of the PC pathway has been corre-
lated to disease severity and mortality in severe bacterial
pneumonia and sepsis [14,15] and continuous intrave-
nous administration of recombinant human (rh-) APC
for four days (Human Activated Protein C Worldwide
Evaluation in Severe Sepsis (PROWESS) trial) has been
shown not only to downregulate activation of coagula-
tion, but also to reduce inflammation and improve sur-
vival in patients with severe sepsis [16]. The benefical
effect of rh-APC in this trial seemed especially prominent
i n  p a t i e n t s  w i t h  s e v e r e  s e p s i s  d u e  t o  p n e u m o n i a  [ 1 7 ] .
While much research has been done on coagulation acti-
vation during severe bacterial infection, data on coagula-
tion activation in viral infection like influenza are sparse.
Evidence that influenza can be associated with coagula-
tion activation comes from a clinical study in pediatric
patients hospitalized for severe influenza [18] and from a
recent study showing elevated plasma levels of thrombin-
antithrombin complexes (TAT c) in mice infected with a
non-lethal dose of influenza A [19]. Interestingly, and as
mentioned above, many elderly patients with influenza
infections suffer from cardiovascular complications.
At present it is unknown whether APC can influence
the procoagulant and inflammatory response to lethal
influenza A infection. Therefore, in the present study we
sought to establish the effect of recombinant mouse (rm)-
APC treatment on local and systemic activation of coagu-
lation and fibrinolysis during lethal H1N1 influenza A in
mice and moreover determined the effect of rm-APC on
lung inflammation, pulmonary viral loads and survival.
We here show, that lethal H1N1 influenza A infection is
associated with both pulmonary and systemic activation
of coagulation and inhibition of fibrinolysis. Moreover,
we show that rm-APC treatment, started 24 hours after
the onset of infection, partially prevents these hemostatic
derangements, but does not impact on lung inflammation
or survival.
Materials and methods
Animals
Male C57BL/6 mice were purchased from Charles River
(Maastricht, the Netherlands) and maintained in the ani-
mal facility of the Academic Medical Center (University
of Amsterdam) according to national guidelines with free
access to food and water. Ten-week-old mice were used in
experiments. All experiments were approved by the Insti-
tutional Animal Care and Use Committee of the Aca-
demic Medical Center.
Experimental infection and treatment
Influenza infection was induced by intranasal instillation
of a lethal dose (28,000 copies) of influenza A/PR/8/34
(H1N1, ATCC no. VR-95; Rockville, MD, USA), as
described [20,21]. This infectious dose was chosen based
on a previous study from our laboratory showing that it
caused lethality in C57BL/6 mice which could be delayed
by eliminating signalling via the proinflammatory recep-
tor for advanced glycation end products (RAGE) [20].
Recombinant murine (rm-) APC and buffer control were
generated by Eli Lilly & Co (Indianapolis, IN, USA) as
described [22]. Rm-APC (2 mg/ml) was diluted in sterile
pyrogen-free saline to a concentration of 625 μg/ml. The
buffer control was diluted likewise. Uninfected mice were
euthanized before or at one, four or eight hours (n = 4 per
time point) after a single intraperitoneal injection of 125
μg of rm-APC (200 μl) to determine plasma APC-levels.
In infection experiments, from 24 hours after infection
on, mice were treated every eight hours for a maximum
of three days with 125 μg of rm-APC or buffer. Sample
harvesting and processing, and determination of viral
copies were done as described (n = 8 per group at each
time point) [20,21].
Assays
M-APC levels were measured by an enzyme capture assay
[23]. TATc (Behringwerke AG, Marburg, Germany),
fibrin degradation products (FDP) [24], plasminogen
activator inhibitor type-1 antigen (PAI-1) [25], myeloper-
oxidase (MPO; HyCult Biotechnology, Uden, the Nether-
lands), interleukin (IL)-1β, keratinocyte-derived
chemokine (KC) and macrophage inflammatory protein
(MIP)-2 (all R&D Systems, Minneapolis, MN, USA) were
measured by ELISA. Plasminogen activator activity
(PAA) was determined by an amidolytic assay [26].
Tumor necrosis factor (TNF)-α, IL-6, IL-12p70, IL-10
and interferon (IFN)-γ were measured by cytometric
bead array (CBA) multiplex assay (BD Biosciences, San
Jose, CA, USA).
Histology and immunohistochemistry
Paraffin lung sections were stained with haematoxylin
and eosin or fluorescein isothiocyanate-labeled anti-
mouse Ly-6G mAb (Pharmingen, San Diego, CA, USA) as
described [27]. To score lung inflammation, the lung sur-
face was analyzed with respect to the following parame-
ters: bronchitis, interstitial inflammation, oedema,
endothelialitis, pleuritis and thrombus formation. Each
parameter was graded on a scale of 0 to 4 (0: absent, 1:
mild, 2: moderate, 3: severe, 4: very severe). The total his-
topathological score was expressed as the sum of the
scores for the different parameters, the maximum being
24. Ly-6G stained slides were photographed with a micro-
scope equipped with a digital camera (Leica CTR500,
Leica Microsystems, Wetzlar, Germany). Stained areas
were analysed with Image Pro Plus (Media Cybernetics,
Bethesda, MD, USA) and expressed as percentage of theSchouten et al. Critical Care 2010, 14:R65
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surface area. The average of 10 pictures was used for
analysis.
Statistical analysis
Data are expressed as box-and-whisker diagrams (depict-
ing the smallest observation, lower quartile, median,
upper quartile and largest observation), medians with
interquartile ranges or as survival curves. Differences
between groups were determined with Kruskal-Wallis,
Mann-Whitney  U  test or log rank test. Analyses were
performed using GraphPad Prism version 4.0 (GraphPad
Software, San Diego, CA, USA). P-values less than 0.05
were considered statistically significant.
Results
Plasma m-APC levels after single dose administration of 
rm-APC
To determine plasma levels of m-APC after single dose
administration of rm-APC, uninfected mice were
injected intraperitoneally with 125 μg of rm-APC (200 μl)
and sacrificed after one, four or eight hours. Plasma levels
o f  r m - A P C  a f t e r  s i n g l e  d o s e  a d m i n i s t r a t i o n  w e r e  1 5 4
(interquartile range 76 to 250), 122 (96 to 131) and 33 (27
to 40) ng/ml after one, four and eight hours, respectively.
Activation of coagulation and downregulation of 
fibrinolysis
Administration of APC has been found to inhibit activa-
tion of coagulation in animals and patients with severe
bacterial sepsis [13,16,28]. To determine the effect of
APC on the procoagulant response in severe influenza,
we infected mice with a lethal dose of influenza A virus
and initiated rm-APC (or buffer control) treatment 24
hours after infection; subsequently, we determined the
levels of TATc and FDP in lung homogenates (Figure 1A,
B) and plasma (Figure 1C, D) at 48 and 96 hours after
infection. Inoculation with a lethal dose of influenza sig-
nificantly increased the levels of TATc and FDP in both
lung homogenates and plasma after 48 and 96 hours as
compared to uninfected control mice. Treatment with
rm-APC strongly inhibited local and systemic activation
of coagulation as shown by decreased levels of TATc and
FDP in rm-APC treated animals in both lungs and plasma
(Figure 1A-D).
Evidence derived from in vitro investigations indicates
that APC may stimulate fibrinolysis by inhibiting the
main inhibitor of this system, PAI-1 [29,30]. To study the
effect of lethal influenza A infection on fibrinolysis and
the impact of rm-APC treatment hereon, we determined
the levels of PAI-1 and PAA in lung homogenates and
plasma. In influenza PAI-1 levels were increased at 48
and 96 hours both locally and systemically as compared
to controls (Figure 2A, C), which was associated with
downregulation of PAA in both lung and plasma (Figure
2B, D). Treatment with rm-APC reduced PAI-1 concen-
trations in lung and plasma, but this was only significant
in plasma 96 hours after infection. Although the effect of
rm-APC on PAI-1 was not significant at 48 hours, rm-
APC treatment did partially preserve fibrinolytic activity
at 48 hours both in lung and plasma, as indicated by
higher PAA as compared to buffer control treated mice
(Figure 2B, D). After 96 hours differences in PAA had
subsided.
Of note, no bleeding complications were seen in mice
treated with rm-APC, except for the occasional small
peritoneal haematomas at the injection site, which were
not seen in buffer control treated mice.
Lung inflammation
Lethal influenza was associated with pulmonary inflam-
mation and damage as evidenced by the occurrence of
bronchitis, interstitial inflammation, oedema and
endothelialitis both at 48 hours (pictures not shown) and
96 hours after infection (Figure 3A, B). There were no dif-
ferences in total histopathological scores between rm-
APC and buffer control treated mice at either 48 or 96
hours after infection (Figure 3C). Moreover, there were
no differences in the separate scores for bronchitis, inter-
stitial inflammation, oedema and endothelialitis (not
shown).
One of the prominent features in lethal influenza is
neutrophil influx into the lung parenchyma both after 48
hours (pictures not shown) and 96 hours (Figure 4A, B).
There were no differences in neutrophil influx between
rm-APC and buffer control treated mice after 48 or 96
hours, as evidenced by equal percentages of positivity in
Ly-6G stainings (Figure 4C). In line, pulmonary MPO
concentrations, indicative for the number of neutrophils
in lung tissue, were similar in both treatment groups at
both time points (Table 1).
To further investigate the effect of rm-APC treatment
on the inflammatory response in severe influenza, we
determined pulmonary levels of various cytokines (TNF-
α, IL-1β, IL-6, IL-10, IL-12p70, IFN-γ) and chemokines
(KC, MIP-2) in lung homogenates obtained 48 and 96
hours after infection. After 48 hours of infection, there
were no statistically significant differences in cytokine
levels between rm-APC and buffer control treated ani-
mals (Table 1). After 96 hours, the levels of the pro-
inflammatory cytokines TNF-α and IL-12p70 were lower
in rm-APC treated animals. Levels of KC and MIP-2 did
not differ between treatment groups at any time point.
Viral load
To investigate the effect of rm-APC on the antiviral
response in influenza infection, we determined viral
loads in lungs over time. Remarkably, after 48 hours, rm-
APC treatment was associated with more than four-foldSchouten et al. Critical Care 2010, 14:R65
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less viral RNA copies as compared to buffer control treat-
ment (Figure 5). However, after 96 hours after infection
this difference in viral load had subsided completely.
Survival
To substantiate whether differences in activation of coag-
ulation, downregulation of fibrinolysis, viral loads and
TNF-α and IL-12p70 levels between rm-APC and buffer
control treated animals were associated with an altered
mortality we performed a survival study. The infection
was associated with 100% lethality within nine days in
both treatment groups and mortality curves did not differ
between rm-APC and buffer control treated mice (Figure
6).
Discussion
Influenza is an important cause of pneumonia, causing 5
to 10% of all CAP cases [4,7]. While bacterial pneumonia
has been linked to activation of coagulation and down-
regulation of anticoagulant mechanisms and fibrinolysis
[10-12], knowledge of the impact of influenza on hemo-
stasis is limited. We here studied alterations in local and
systemic activation of coagulation and fibrinolysis
together with induction of inflammation during lethal
influenza A infection. In addition, considering that previ-
ous investigations in patients and animals have especially
pointed to beneficial effects of APC treatment in the
lungs [17,31-33], we determined the effect of APC on the
procoagulant and inflammatory response to and the out-
come of lethal influenza. We show that lethal H1N1 influ-
enza A infection is associated with extensive pulmonary
and systemic activation of coagulation accompanied by
inhibition of fibrinolysis. Systemic administration of
APC, started 24 hours after infection, mimicking a possi-
ble clinical scenario, strongly attenuated coagulation acti-
vation and partially reversed inhibition of fibrinolysis, but
did not influence lung inflammation or survival.
Concurrent alterations in coagulation and fibrinolysis
during influenza have not been studied in detail thus far.
One clinical study in children has indicated that severe
influenza can be associated with disseminated intravas-
cular coagulation [18]. In addition, mice with non-lethal
influenza A infection displayed a rise in plasma TATc and
PAI-1 levels; although fibrinolytic activity (such as mea-
Figure 1 Activation of coagulation in lethal H1N1 influenza A infection is attenuated by recombinant murine activated protein C treat-
ment. Levels of A. and C. thrombin-antithrombin complexes (TATc) and B. and D. fibrin degradation products (FDP) in A. and B. lung and C. and D. 
plasma at baseline (dashed) and 48 and 96 hours after induction of lethal influenza A infection in buffer control treated mice (white) and recombinant 
murine activated protein C treated mice (grey). Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, 
median, upper quartile and largest observation (eight mice per group at each time point). ## and ### indicate statistical significance as compared to 
baseline (P < 0.01 and P < 0.001 respectively, Mann-Whitney U test), ** and *** indicate statistical significance as compared to buffer control (P < 0.01 
and P < 0.001 respectively, Mann-Whitney U test).Schouten et al. Critical Care 2010, 14:R65
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sured by PAA) was not determined in this previous inves-
tigation, these data point to concurrent activation of
coagulation and inhibition of fibrinolysis at the systemic
level during mild influenza [19]. Our own preliminary
data have suggested that lethal influenza not only results
in systemic coagulation activation, but also in induction
of the coagulation system in the lungs (Schouten et al,
XXIst Congress of the International Society of Thrombo-
sis and Haemostasis, Boston, July 2009, abstract no.
3065). Our current results confirm and expand these pre-
vious data. First, we demonstrate local and systemic acti-
vation of coagulation, as evidenced by increased lung and
plasma TATc and FDP levels in influenza infected mice at
48 and 96 hours. Moreover, we show that activation of
coagulation is accompanied by local as well as systemic
downregulation of fibrinolysis, as reflected by elevated
PAI-1 and reduced PAA levels in lung homogenates and
plasma, which probably further contributes to the influ-
enza-induced procoagulant state. Most likely, the down-
regulation of fibrinolytic activity can be explained at least
partially by upregulation of PAI-1, the main inhibitor of
the fibrinolytic system. As such, severe influenza appears
to cause similarly opposite changes in pulmonary coagu-
lation and fibrinolysis as previously reported for bacterial
pneumonia and acute respiratory distress syndrome [34-
37].
Systemic administration of rm-APC strongly inhibited
activation of the coagulation system, as indicated by
markedly reduced plasma and lung concentrations of
TATc and FDPs in rm-APC treated mice relative to vehi-
cle treated animals. In addition, rm-APC had a modest
but statistically significant effect on the fibrinolytic sys-
tem, partially blunting the influenza-induced rise in
plasma and lung PAI-1 levels and partially preserving
plasma and lung fibrinolytic activity. The capacity of APC
to attenuate systemic coagulation during severe bacterial
infection has been demonstrated in several studies
[13,16,38]. Our group previously reported on the effects
of intravenous administration of recombinant APC on
pulmonary coagulation in healthy humans intrabronchi-
ally challanged with lipopolysaccharide (LPS) [39] and in
rats challenged with LPS systemically [40] or with viable
Figure 2 Induction of plasminogen activator inhibitor type-1 and downregulation of fibrinolysis in lethal H1N1 influenza A infection is par-
tially reversed by recombinant murine activated protein C treatment. Levels of A. and C. plasminogen activator inhibitor type-1 (PAI-1) and B. 
and D. plasminogen activator activity (PAA) in A. and B. lung and C. and D. plasma at baseline (dashed) and 48 and 96 hours after induction of lethal 
influenza A infection in buffer control treated mice (white) and recombinant murine activated protein C treated mice (grey). Data are expressed as 
box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation (eight mice per group 
at each time point). # and ## indicate statistical significance as compared to baseline (P < 0.05 and P < 0.01 respectively, Mann-Whitney U test), * and 
** indicate statistical significance as compared to buffer control (P < 0.05 and P < 0.01 respectively, Mann-Whitney U test).Schouten et al. Critical Care 2010, 14:R65
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bacteria via the airways [41,42]. All of these previous
studies [39-42], in which APC treatment was started
before the challenge with LPS or bacteria, revealed the
capacity of APC to inhibit coagulation in the lungs. The
current study adds to these earlier findings that APC is
capable of inhibiting systemic and local coagulation dur-
ing influenza-induced pneumonia and that this effect is
present when APC administration is initiated 24 hours
after infection, that is, in a clinically more relevant set-
ting. Of interest, endogenous APC may also reduce influ-
enza-induced coagulation, as indicated by studies in mice
with a mutation in their thrombomodulin  gene that
results in a minimal capacity for endogenous APC gener-
ation: these mice demonstrated increased plasma levels
of TATc (relative to wild-type mice) during non-lethal
influenza [19]. Our finding that rm-APC stimulated
fibrinolysis by inhibiting PAI-1 is supported by evidence
derived from in vitro investigations [29,30]. Of note, pre-
vious studies from our laboratory could not demonstrate
an effect of recombinant APC on pulmonary fibrinolysis
during LPS-induced lung injury [39,40] or bacterial pneu-
monia [41,42].
Besides anticoagulant and profibrinolytic properties,
APC has been found to exert anti-inflammatory activity
(reviewed in [13]). Previous studies have suggested that
recombinant APC can inhibit LPS-induced neutrophil
recruitment and activation in the lungs [31,43]. Nonethe-
less, in the current study rm-APC did not have a major
impact on lung inflammation during lethal influenza A
infection, as indicated by similar histopathology scores of
lung tissue, a similar influx of neutrophils to the site of
infection and largely similar cytokine and chemokine
concentrations in lung homogenates. Interestingly, rm-
APC did reduce lung TNF-α and IL-12 levels 96 hours
after infection; similarly, APC has been found to inhibit
the LPS-induced production of TNF-α in vitro and  in
vivo [32,44].
To our knowledge, the effect of APC on antiviral
defense per se has not been studied. We here show that
rm-APC temporarily lowers pulmonary viral loads about
four-fold, as measured 48 hours after infection. These dif-
Figure 3 Lung histopathology in lethal H1N1 influenza A infection is not influenced by recombinant murine activated protein C treatment. 
Representative slides of lung haematoxylin and eosin staining 96 hours after induction of lethal influenza A infection in A. buffer control treated mice 
and B. recombinant murine activated protein C treated mice (original magnification × 100). C. Total pathology score (described in methods section) 
48 and 96 hours after induction of lethal influenza A infection in buffer control treated mice (white) and recombinant murine activated protein C treat-
ed mice (grey). Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest 
observation (eight mice per group at each time point). No statistical differences between the groups at each time point.Schouten et al. Critical Care 2010, 14:R65
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Figure 4 Lung neutrophil influx in lethal H1N1 influenza A infection is not influenced by recombinant murine activated protein C treat-
ment. Representative slides of lung Ly-6G staining (brown) 96 hours after induction of lethal influenza A infection in A. buffer control treated mice 
and B. recombinant murine activated protein C treated mice (original magnification × 100). C. Quantitation of pulmonary Ly-6G content 48 and 96 
hours after induction of lethal influenza A infection in buffer control treated mice (white) and recombinant murine activated protein C treated mice 
(grey). Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest obser-
vation (eight mice per group at each time point). No statistical differences between the groups at each time point.
Table 1: Pulmonary myeloperoxidase, cytokine and chemokine levels 48 and 96 hours after induction of lethal H1N1 
influenza A infection
Placebo rm-APC placebo rm-APC
MPO (ng/ml) 5.0 (3.9 to 5.9) 4.9 (4.2 to 5.1) 6.4 (5.6 to 6.9) 6.8 (6.2 to 8.9)
TNF-α (pg/ml) 120 (97 to 134) 121 (101 to 143) 393 (293 to 495) 167 (139 to 344) *
IL-1β (pg/ml) 236 (100 to 415) 389 (331 to 389) 479 (444 to 549) 371 (345 to 587)
IL-6 (ng/ml) 0.9 (0.7 to 1.0) 0.8 (0.7 to 0.9) 1.3 (1.0 to 1.6) 1.0 (0.7 to 1.3)
IL-12 (pg/ml) B.D. B.D. 54 (37 to 64) 11 (5.0 to 28) *
IL-10 (pg/ml) 137 (86 to 165) 131 (101 to 153) 115 (82 to 175) 65 (23 to 147)
IFN-γ (pg/ml) 6.8 (6.0 to 9.7) 6.9 (5.8 to 7.9) 6.7 (4.9 to 8.1) 5.6 (3.5 to 7.9)
KC (ng/ml) 3.1 (2.3 to 3.7) 4.0 (2.9 to 5.1) 3.4 (2.6 to 4.4) 4.2 (3.3 to 5.6)
MIP-2 (ng/ml) 1.2 (0.8 to 1.4) 1.5 (1.2 to 1.6) 1.4 (1.3 to 1.5) 1.5 (1.4 to 1.7)
Data are medians (interquartile ranges) of eight mice per group at each time point. * indicates statistical significance compared to placebo 
(P < 0.05). MPO, myeloperoxidase, TNF-α, tumor necrosis factor-α, IL, interleukin, IFN-γ, interferon-γ, KC, keratinocyte-derived chemokine, 
MIP-2, macrophage inflammatory protein-2, B.D., below detection.Schouten et al. Critical Care 2010, 14:R65
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ferences between rm-APC and vehicle treated mice had
disappeared 96 hours post infection. The transiently
reduced viral loads in rm-APC treated animals are sur-
prising considering that APC is not known to impact on
antiviral mechanisms and did not influence the inflam-
matory response to influenza A in a way that might have
improved host defense. The difference in viral load
between rm-APC and buffer treated mice did not result
in a substantially changed inflammatory response or a
delayed mortality. However, since we tested only one
infectious dose of influenza A, we cannot exclude that
rm-APC does impact on lethality after infection with dif-
ferent viral doses. The mechanism by which rm-APC
reduces viral loads at an early stage of influenza infection
needs further investigation. Besides anticoagulant and
anti-inflammatory properties, APC has been described to
influence the hemodynamic response to an inflammatory
stimulus [13,45]. The potential effect of rm-APC on
hemodynamics was not measured in our current study
and therefore warrants further investigation.
In order to mimic the clinical situation, APC should be
administered by a continuous intravenous infusion. How-
ever, this is difficult to achieve in mice for a period of sev-
eral days. In this study, we therefore administered rm-
APC intraperitoneally every eight hours at a dose of 125
μg (a daily dose of approximately 15 mg/kg, that is,
approximately 25 times higher than the daily dose admin-
istered to humans). This administration protocol resulted
in plasma levels which were not dissimilar to the levels
observed after intravenous administration of lower doses
in previous studies in rodents in which anti-inflammatory
effects of recombinant APC were demonstrated after LPS
administration [31,32,46,47] and which are in the same
range as those achieved by continuous intravenous infu-
sion in septic patients [48]. In light of these earlier rodent
and patient investigations [31,32,46-48] and considering
that the APC dosing schedule used here caused profound
anticoagulant effects, we consider it unlikely that higher
APC doses would have had a significant effect on lung
inflammation or survival. Such studies would be less clin-
ically relevant and moreover would be associated with an
increased risk for bleeding, which was not observed with
the current dosing regimen. It would be of considerable
interest, however, to study the effects of mutant forms of
APC with reduced anticoagulant but enhanced cytopro-
tective properties in models of lethal influenza [46,47,49].
Conclusions
Lethal H1N1 influenza infection is associated with both
pulmonary and systemic activation of coagulation and
inhibition of fibrinolysis. Rm-APC treatment, started 24
hours after the onset of infection, partially prevents these
hemostatic derangements, but does not impact on lung
inflammation or survival.
Key messages
• Lethal H1N1 influenza infection is associated with
both pulmonary and systemic activation of coagula-
tion and inhibition of fibrinolysis.
• Rm-APC treatment, started 24 hours after the onset
of lethal H1N1 infection, partially prevents influenza-
induced procoagulant and anti-fibrinolytic derange-
ments.
Figure 5 Pulmonary viral loads in lethal H1N1 influenza A infec-
tion are transiently reduced by recombinant murine activated 
protein C treatment. Lung viral RNA copies 48 and 96 hours after in-
duction of lethal influenza A infection in buffer control treated mice 
(white) and recombinant murine activated protein C treated mice 
(grey). Data are expressed as box-and-whisker diagrams depicting the 
smallest observation, lower quartile, median, upper quartile and larg-
est observation (eight mice per group at each time point). * indicates 
statistical significance as compared to buffer control (P < 0.05, Mann-
Whitney U test).
Figure 6 Survival in lethal H1N1 influenza A infection is not af-
fected by recombinant murine activated protein C treatment. Sur-
vival of buffer control treated mice (open squares, n = 12) and 
recombinant murine activated protein C treated mice (grey squares, n 
= 12) in lethal influenza A infection. No statistical differences between 
the groups (log rank test).Schouten et al. Critical Care 2010, 14:R65
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• Rm-APC treatment, started 24 hours after the onset
of lethal H1N1 infection, does not impact on lung
inflammation or survival.
Abbreviations
APC: activated protein C; CAP: community-acquired pneumonia; CBA: cyto-
metric bead array; FDP: fibrin degradation products; IFN-γ: interferon-γ; IL:
interleukin; LPS: lipopolysaccharide; KC: keratinocyte-derived chemokine; MIP-
2: macrophage inflammatory protein-2; MPO: myeloperoxidase; PAA: plasmi-
nogen activator activity; PAI-1: plasminogen activator inhibitor-1; RAGE: recep-
tor for advanced glycation end products; rh-/rm-: recombinant human/mouse;
TATc: thrombin-antithrombin complexes; TNF-α: tumor necrosis factor-α.
Competing interests
Bruce Gerlitz and Brian Grinnell are employed by Lilly Research Laboratories, a
division of Eli Lilly & Co, which produces recombinant human APC for the treat-
ment of severe sepsis. The other authors declare they have no conflicts of inter-
ests.
Authors' contributions
MS participated in the design of the study, carried out the in vivo experiments
and drafted the manuscript. KFS participated in the design of the study and
helped to draft the manuscript. BG and BWG provided the rm-APC and partici-
pated in the design of the study. JJTHR performed pathology scoring, prepared
part of the figures and helped to draft the manuscript. ML performed coagula-
tion measurements and helped to draft the manuscript. CV participated in the
design of the study, advised in laboratory matters and helped to draft the man-
uscript. TP participated in the design of the study, supervised the study and
helped to draft the manuscript. All authors read and approved the manuscript.
Acknowledgements
The authors thank Marieke ten Brink and Joost Daalhuisen for their technical 
assistance during the animal experiments, Regina de Beer for performing his-
topathological and immunohistochemical staining. Marcel Schouten is sup-
ported by a research grant of the Dutch Thrombosis Foundation (grant 
number TSN 2005-1).
Author Details
1Center for Experimental and Molecular Medicine (CEMM), Academic Medical 
Center, University of Amsterdam, Meibergdreef 9, Room G2-130, 1105 AZ, 
Amsterdam, The Netherlands, 2Center for Infection and Immunity Amsterdam 
(CINIMA), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 
Room G2-130, 1105 AZ, Amsterdam, The Netherlands, 3Laboratory of 
Experimental Immunology, Academic Medical Center, University of 
Amsterdam, Meibergdreef 9, Room G2-130, 1105 AZ, Amsterdam, The 
Netherlands, 4Department of Pulmonology; Academic Medical Center, 
Academic Medical Center, University of Amsterdam, Meibergdreef 9, Room G2-
130, 1105 AZ, Amsterdam, The Netherlands, 5Biotechnology Discovery 
Research, Lilly Research Laboratories; Lilly Corporate Center, Indianapolis, 
Indiana, IN 46285-0444, USA, 6Department of Pathology, Academic Medical 
Center, University of Amsterdam, Meibergdreef 9, Room G2-130, 1105 AZ, 
Amsterdam, The Netherlands and 7Department of Internal Medicine, 
Academic Medical Center, University of Amsterdam, Meibergdreef 9, Room G2-
130, 1105 AZ, Amsterdam, The Netherlands
References
1. Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L: Mortality due to 
influenza in the United States--an annualized regression approach 
using multiple-cause mortality data.  Am J Epidemiol 2006, 163:181-187.
2. Smith GJ, Bahl J, Vijaykrishna D, Zhang J, Poon LL, Chen H, Webster RG, 
Peiris JS, Guan Y: Dating the emergence of pandemic influenza viruses.  
Proc Natl Acad Sci USA 2009, 106:11709-11712.
3. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, 
Quinones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, 
Ormsby CE, Corrales A, Higuera A, Mondragon E, Cordova-Villalobos JA: 
Pneumonia and respiratory failure from swine-origin Influenza. A 
(H1N1) in Mexico.  N Engl J Med 2009, 361:680-689.
4. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of 
myocardial infarction and stroke after acute infection or vaccination.  N 
Engl J Med 2004, 351:2611-2618.
5. Blanquer J, Blanquer R, Borras R, Nauffal D, Morales P, Menendez R, Subias 
I, Herrero L, Redon J, Pascual J: Aetiology of community acquired 
pneumonia in Valencia, Spain: a multicentre prospective study.  Thorax 
1991, 46:508-511.
6. Nauffal D, Menendez R, Morales P, Gonzalez-Granda D, Blanquer J, 
Blanquer R, Borras R, Millan E, Subias I, Aycart MD: Community viral 
pneumonia in the adult population: a prospective multicenter study of 
62 cases. The Pneumonia Study Group of the Community of Valencia.  
Rev Clin Esp 1990, 187:229-232.
7. Lauderdale TL, Chang FY, Ben RJ, Yin HC, Ni YH, Tsai JW, Cheng SH, Wang 
JT, Liu YC, Cheng YW, Chen ST, Fung CP, Chuang YC, Cheng HP, Lu DC, Liu 
CJ, Huang IW, Hung CL, Hsiao CF, Ho M: Etiology of community acquired 
pneumonia among adult patients requiring hospitalization in Taiwan.  
Respir Med 2005, 99:1079-1086.
8. Beigel JH: Influenza.  Crit Care Med 2008, 36:2660-2666.
9. Schouten M, Wiersinga WJ, Levi M, Poll T van der: Inflammation, 
endothelium, and coagulation in sepsis.  J Leukoc Biol 2008, 83:536-545.
10. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, 
Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W: Alveolar 
fibrin formation caused by enhanced procoagulant and depressed 
fibrinolytic capacities in severe pneumonia - Comparison with the 
acute respiratory distress syndrome.  Am J Respir Crit Care Med 2000, 
161:454-462.
11. Choi G, Schultz MJ, Levi M, Poll T van der, Millo JL, Garrard CS: Protein C in 
pneumonia.  Thorax 2005, 60:705-706.
12. Rijneveld AW, Florquin S, Bresser P, Levi M, De Waard V, Lijnen R, Zee JS 
Van der, Speelman P, Carmeliet P, Poll T van der: Plasminogen activator 
inhibitor type-1 deficiency does not influence the outcome of murine 
pneumococcal pneumonia.  Blood 2003, 102:934-939.
13. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C 
pathway.  Blood 2007, 109:3161-3172.
14. Macias WL, Nelson DR: Severe protein C deficiency predicts early death 
in severe sepsis.  Crit Care Med 2004, 32:S223-S228.
15. Vail GM, Xie YJ, Haney DJ, Barnes CJ: Biomarkers of thrombosis, 
fibrinolysis, and inflammation in patients with severe sepsis due to 
community-acquired pneumonia with and without Streptococcus 
pneumoniae.  Infection 2009, 37:358-364.
16. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-
Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: 
Efficacy and safety of recombinant human activated protein C for 
severe sepsis.  N Engl J Med 2001, 344:699-709.
17. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki 
DG, Bates B, Yan SCB, Dhainaut JF: Severe community-acquired 
pneumonia as a cause of severe sepsis: data from the PROWESS study.  
Crit Care Med 2005, 33:952-961.
18. Watanabe T, Yoshikawa H, Abe Y, Yamazaki S, Uehara Y, Abe T: Renal 
involvement in children with influenza A virus infection.  Pediatr 
Nephrol 2003, 18:541-544.
19. Keller TT, Sluijs KF Van der, De Kruif MD, Gerdes VEA, Meijers JCM, Florquin 
S, Poll T van der, Van Gorp ECM, Brandjes DPM, Büller HR, Levi M: Effects 
on coagulation and fibrinolysis induced by influenza in mice with a 
reduced capacity to generate activated protein C and a deficiency in 
plasminogen activator inhibitor type 1.  Circ Res 2006, 99:1261-1269.
20. Van Zoelen MA, Sluijs KF Van der, Achouiti A, Florquin S, Braun-Pater JM, 
Yang H, Nawroth PP, Tracey KJ, Bierhaus A, Poll T van der: Receptor for 
advanced glycation end products is detrimental during influenza A 
virus pneumonia.  Virology 2009, 391:265-273.
21. Sluijs KF Van der, Van Elden LJ, Arens R, Nijhuis M, Schuurman R, Florquin 
S, Kwakkel J, Akira S, Jansen HM, Lutter R, Poll T van der: Enhanced viral 
clearance in interleukin-18 gene-deficient mice after pulmonary 
infection with influenza A virus.  Immunology 2005, 114:112-120.
22. Berg DT, Gerlitz B, Shang J, Smith T, Santa P, Richardson MA, Kurz KD, 
Grinnell BW, Mace K, Jones BE: Engineering the proteolytic specificity of 
activated protein C improves its pharmacological properties.  Proc Natl 
Acad Sci USA 2003, 100:4423-4428.
23. Li W, Zheng X, Gu J, Hunter J, Ferrell GL, Lupu F, Esmon NL, Esmon CT: 
Overexpressing endothelial cell protein C receptor alters the 
hemostatic balance and protects mice from endotoxin.  J Thromb 
Haemost 2005, 3:1351-1359.
Received: 14 January 2010 Revised: 25 March 2010 
Accepted: 14 April 2010 Published: 14 April 2010
This article is available from: http://ccforum.com/content/14/2/R65 © 2010 Schouten et al.; licensee BioMed Central Ltd.  This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Critical Care 2010, 14:R65Schouten et al. Critical Care 2010, 14:R65
http://ccforum.com/content/14/2/R65
Page 10 of 10
24. Elms MJ, Bundesen PG, Rowbury D, Goodall S, Wakeham N, Rowell JA, 
Hillyard CJ, Rylatt DB: Automated-determination of cross-linked fibrin 
derivatives in plasma.  Blood Coagul Fibrinolysis 1993, 4:159-164.
25. Verheijen JH, Wijngaards G, Kluft C, Chang G, Mullaart E, Preston FE: A 
simple, sensitive spectrophotometric assay for extrinsic (tissue-type) 
plasminogen activator applicable to measurements in plasma.  Thromb 
Haemost 1982, 48:266-269.
26. Verheijen JH, Chang GTG, Kluft C: Evidence for the occurrence of a fast-
acting inhibitor for tissue-type plasminogen-activator in human-
plasma.  Thromb Haemost 1984, 51:392-395.
27. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, Poll T van der: 
Urokinase receptor is necessary for adequate host defense against 
pneumococcal pneumonia.  J Immunol 2002, 168:3507-3511.
28. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE: 
Protein C prevents the coagulopathic and lethal effects of Escherichia 
coli infusion in the baboon.  J Clin Invest 1987, 79:918-925.
29. Bajzar L, Nesheim ME, Tracy PB: The profibrinolytic effect of activated 
protein C in clots formed from plasma is TAFI-dependent.  Blood 1996, 
88:2093-2100.
30. Taylor FB, Lockhart MS: Whole-blood clot lysis - In vitro modulation by 
activated protein C.  Thromb Res 1985, 37:639-649.
31. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, 
Takatsuki K: Activated protein C attenuates endotoxin-induced 
pulmonary vascular injury by inhibiting activated leukocytes in rats.  
Blood 1996, 87:642-647.
32. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, 
Takatsuki K: Activated protein C prevents LPS-induced pulmonary 
vascular injury by inhibiting cytokine production.  Am J Physiol 1997, 
272:L197-L202.
33. Suzuki K, Gabazza C, Hayashi T, Kamada H, Adachi Y, Taguchi O: Protective 
role of activated protein C in lung and airway remodeling.  Crit Care 
Med 2004, 32:S262-S265.
34. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, Poll T van 
der: Local activation of coagulation and inhibition of fibrinolysis in the 
lung during ventilator associated pneumonia.  Thorax 2004, 59:130-135.
35. Gunther A, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky 
HG, Morr H, Grimminger F, Walmrath D, Seeger W: Enhanced tissue 
factor pathway activity and fibrin turnover in the alveolar 
compartment of patients with interstitial lung disease.  Thromb 
Haemost 2000, 83:853-860.
36. Choi G, Schultz MJ, Van Till JW, Bresser P, Zee JS Van der, Boermeester MA, 
Levi M, Poll T van der: Disturbed alveolar fibrin turnover during 
pneumonia is restricted to the site of infection.  Eur Respir J 2004, 
24:786-789.
37. Rijneveld AW, Weijer S, Bresser P, Florquin S, Vlasuk GP, Rote WE, Spek CA, 
Reitsma PH, Zee JS Van der, Levi M, Poll T van der: Local activation of the 
tissue factor-factor VIIa pathway in patients with pneumonia and the 
effect of inhibition of this pathway in murine pneumococcal 
pneumonia.  Crit Care Med 2006, 34:1725-1730.
38. Levi M: Activated protein C in sepsis: a critical review.  Curr Opin Hematol 
2008, 15:481-486.
39. Poll T van der, Levi M, Nick JA, Abraham E: Activated protein C inhibits 
local coagulation after intrapulmonary delivery of endotoxin in 
humans.  Am J Respir Crit Care Med 2005, 171:1125-1128.
40. Choi G, Vlaar APJ, Schouten M, Van't Veer C, Poll T van der: Natural 
anticoagulants limit lipopolysaccharide-induced pulmonary 
coagulation but not inflammation.  Eur Respir J 2007, 30:423-428.
41. Choi G, Hofstra JJH, Roelofs JJTH, Florquin S, Bresser P, Levi M, Poll T van 
der, Schultz MJ: Recombinant human activated protein C inhibits local 
and systemic activation of coagulation without influencing 
inflammation during Pseudomonas aeruginosa pneumonia in rats.  Crit 
Care Med 2007, 35:1362-1368.
42. Choi G, Hofstra JJH, Roelofs JJTH, Rijneveld AW, Bresser P, Zee JS Van der, 
Florquin S, Poll T van der, Levi M, Schultz MJ: Antithrombin inhibits 
bronchoalveolar activation of coagulation and limits lung injury 
during Streptococcus pneumoniae pneumonia in rats.  Crit Care Med 
2008, 36:204-210.
43. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, 
Zarini S, Murphy RC, Kuhn K, Richter D, Kast KR, Abraham E: Recombinant 
human activated protein C reduces human endotoxin-induced 
pulmonary inflammation via inhibition of neutrophil chemotaxis.  
Blood 2004, 104:3878-3885.
44. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill 
L, Kelleher D, Schwarz HP, Smith OP: Activated protein C inhibits 
lipopolysaccharide-induced nuclear translocation of nuclear factor 
kappa B (NF-kappa B) and tumour necrosis factor alpha (TNF-alpha) 
production in the THP-1 monocytic cell line.  Br J Haematol 2000, 
110:130-134.
45. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, 
Nelson DR, Lowry SF: Effects of drotrecogin alfa (activated) in human 
endotoxemia.  Shock 2004, 21:222-229.
46. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, 
Castellino FJ, Mackman N, Griffin JH, Weiler H: Endotoxemia and sepsis 
mortality reduction by non-anticoagulant activated protein C.  J Exp 
Med 2007, 204:2439-2448.
47. Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, 
Fernandez JA, Yang XV, Riewald M, Weiler H, Ruggeri ZM, Griffin JH: 
Hyper-antithrombotic, non-cytoprotective Glu149Ala-activated 
protein C mutant.  Blood 2009, 113:5970-5978.
48. Macias WL, Dhainaut JF, Yan SCB, Helterbrand JD, Seger M, Johnson G, 
Small DS: Pharmacokinetic-pharmacodynamic analysis of drotrecogin 
alfa (activated) in patients with severe sepsis.  Clin Pharmacol Ther 2002, 
72:391-402.
49. Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S, Galbreath EJ, 
Swanson BA, Jones BE, Grinnell BW: Distinct functions of activated 
protein C differentially attenuate acute kidney injury.  J Am Soc Nephrol 
2009, 20:267-277.
doi: 10.1186/cc8964
Cite this article as: Schouten et al., Activated protein C ameliorates coagul-
opathy but does not influence outcome in lethal H1N1 influenza: a con-
trolled laboratory study Critical Care 2010, 14:R65